About: The Emerging Role of Convalescent Plasma in the Treatment of COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The Emerging Role of Convalescent Plasma in the Treatment of COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	The Emerging Role of Convalescent Plasma in the Treatment of COVID-19
Creator	Tsiodras, Sotirios Pavlakis, George Dimopoulos, Meletios Psaltopoulou, Theodora Terpos, Evangelos Pappa, Vasiliki Politou, Marianna Sergentanis, Theodoros
source	Medline; PMC
abstract	Various agents are currently under evaluation as potential treatments in the fight against coronavirus disease 2019 (COVID-19). Plasma from patients that have overcome COVID-19 infection, referred to as convalescent plasma, is a treatment option with considerable background in viral diseases such as Spanish influenza, H1N1, Ebola, Severe Acute Respiratory Syndrome (SARS), and Middle East Respiratory Syndrome (MERS). Although convalescent plasma has historically proven beneficial in the treatment of some viral diseases, its use is still explorative in the context of COVID-19. To date, preliminary evidence from case series is favorable as significant clinical, biochemical improvement and hospital discharge have been reported. A detailed overview of randomized as well non-randomized trials of treatment with convalescent plasma, which have been registered worldwide, is provided in this review. Based on these studies, data from thousands of patients is anticipated in the near future. Convalescent plasma seems to be a safe option, but potential risks such as transfusion-related acute lung injury and antibody-dependent enhancement are discussed. Authorities including the Food and Drug Administration (FDA), and scientific associations such as the International Society of Blood Transfusion (ISBT) and the European Blood Alliance (EBA), have provided guidance into the selection criteria for donors and recipients. A debatable, pivotal issue pertains to the optimal timing of convalescent plasma transfusion. This treatment should be administered as early as possible to maximize efficacy, but at the same time be reserved for severe cases. Emerging risk stratification algorithms integrating clinical and biochemical markers to trace the cases at risk of significant deterioration can prove valuable in this direction.
has issue date	2020-05-21(xsd:dateTime)
bibo:doi	10.1097/hs9.0000000000000409
bibo:pmid	32647807
has license	cc-by-nc-nd
sha1sum (hex)	d4341155a17dcc37c941a941cb0a226d6300b693
schema:url	https://doi.org/10.1097/hs9.0000000000000409
resource representing a document's title	The Emerging Role of Convalescent Plasma in the Treatment of COVID-19
has PubMed Central identifier	PMC7306310
has PubMed identifier	32647807
schema:publication	Hemasphere
resource representing a document's body	covid:d4341155a17dcc37c941a941cb0a226d6300b693#body_text
is schema:about of	named entity 'COVID-19' named entity 'evaluation' named entity 'COVID' named entity 'Convalescent Plasma' named entity 'blood donors' named entity 'immune globulin' named entity 'COVID' named entity 'convalescent plasma' named entity 'Convalescent plasma' named entity 'infusion' named entity 'China' named entity 'cytokine' named entity 'viral diseases' named entity 'hyperimmune globulin' named entity 'China' named entity 'convalescent plasma' named entity 'acute respiratory distress syndrome' named entity 'pneumococcal pneumonia' named entity 'IgM' named entity 'titer' named entity 'antimalarial agent' named entity 'ISBT' named entity 'clinical studies' named entity 'Nanjing' named entity 'lymphopenia' named entity 'Mexico' named entity 'lung' named entity 'high-risk' named entity 'COVID' named entity 'Korea' named entity 'infection' named entity 'diagnostic test' named entity 'MERS-coronavirus' named entity 'antibody' named entity 'antiviral' named entity 'antibodies' named entity 'convalescent plasma' named entity 'convalescent plasma therapy' named entity 'influenza pandemic' named entity 'hepatitis B immune globulin' named entity 'convalescent plasma' named entity 'SARS-CoV-2' named entity 'Ebola virus disease outbreak' named entity 'titer' named entity 'C-reactive protein' named entity 'interleukin-6 receptor' named entity 'plasmapheresis' named entity 'Guangdong' named entity 'prognosis' named entity 'weaning' named entity 'adverse event' named entity 'human leukocyte antigen' named entity 'viral diseases' named entity 'antibodies' named entity 'infection' named entity 'intubation' named entity 'China' named entity 'viremia' named entity 'study protocols' named entity 'China' named entity 'seroconversion' named entity 'antibody-dependent cellular cytotoxicity' named entity 'pneumonia' named entity 'International Society of Blood Transfusion' named entity 'case series' named entity 'neutralizing antibodies' named entity 'virus' named entity 'HCV' named entity 'TRALI' named entity 'passive immunity' named entity 'antibody' named entity 'convalescent plasma' named entity 'COVID-19 pandemic' named entity 'Health and Food Safety'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software